Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBILUP
2024-516242-19-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of obinutuzumab in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Complete renal response at week 52. Planned start Nov 2024; status: authorised.
02
Drugs
obinutuzumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2024-516242-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516242-19-00.